Style de citation APA (7e éd.)

Xu, C., Zhang, L., Wang, D., Jiang, S., Cao, D., Zhao, Z., . . . Jin, J. (2021). Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer. Nature Publishing Group.

Style de citation Chicago (17e éd.)

Xu, Chuncao, Lei Zhang, Daifei Wang, Shiqin Jiang, Di Cao, Zhongxiang Zhao, Min Huang, et Jing Jin. Lipidomics Reveals That Sustained SREBP-1-dependent Lipogenesis Is a Key Mediator of Gefitinib-acquired Resistance in EGFR-mutant Lung Cancer. Nature Publishing Group, 2021.

Style de citation MLA (8e éd.)

Xu, Chuncao, et al. Lipidomics Reveals That Sustained SREBP-1-dependent Lipogenesis Is a Key Mediator of Gefitinib-acquired Resistance in EGFR-mutant Lung Cancer. Nature Publishing Group, 2021.